Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition

Lars Bräutigam1, Linda Pudelko2, Ann-Sofie Jemth2

  • 1Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. lars.brautigam@scilifelab.se thomas.helleday@scilifelab.se.

Cancer Research
|February 11, 2016
PubMed

Insights

MTH1 inhibition targets cancer cells by exploiting their redox imbalance. Antioxidants protect against MTH1 inhibition, suggesting a therapeutic strategy for cancers with deregulated hypoxia signaling.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Cancer Research

Background:

  • Cancer cells exhibit redox imbalance, driving growth and survival.
  • MTH1 (NUDT1) detoxifies oxidized nucleotides, compensating for oxidative stress.
  • Upregulation of MTH1 is a non-oncogenic addiction in cancer cells.

Purpose of the Study:

  • To investigate the role of oxidative stress in MTH1 inhibition sensitivity.
  • To explore MTH1 as a therapeutic target in cancers with hypoxia signaling.
  • To utilize zebrafish as a model for studying MTH1 biology and cancer therapeutics.

Main Methods:

  • Studied the effect of oxidative stress modulation on MTH1 inhibition in cells.
  • Purified zebrafish MTH1 and determined its crystal structure with an inhibitor.
  • Utilized zebrafish embryos and transgenic lines to model hypoxia and monitor redox status in vivo.
  • Administered oxidized nucleotides to assess MTH1 activity's role in embryo toxicity.

Main Results:

  • Increased oxidative stress sensitized non-malignant cells to MTH1 inhibition.
  • Decreased oxidative stress protected cancer cells against MTH1 inhibition.
  • Zebrafish MTH1 structure revealed insights into its biology.
  • Hypoxia signaling activation sensitized zebrafish embryos to MTH1 inhibition.
  • Antioxidant treatment protected against MTH1 inhibition in hypoxia-activated zebrafish.

Conclusions:

  • MTH1 inhibition is a potential therapeutic strategy for cancers with redox imbalance.
  • Targeting MTH1 may be effective in cancers exhibiting deregulated hypoxia signaling.
  • Zebrafish serve as a valuable model for studying MTH1-targeted cancer therapies.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K